Home Cart Sign in  
Chemical Structure| 2169232-81-7 Chemical Structure| 2169232-81-7

Structure of Magrolimab
CAS No.: 2169232-81-7

Chemical Structure| 2169232-81-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Magrolimab is a humanized IgG4 monoclonal antibody that prevents CD47 from binding to Signal Regulatory Protein α (SIRPα). Magrolimab has potential for research in various cancers.

Synonyms: Hu5F9-G4

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Magrolimab

CAS No. :2169232-81-7
M.W : 145.74 kDa
SMILES Code : NONE
Synonyms :
Hu5F9-G4
MDL No. :N/A

Safety of Magrolimab

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
TC32 cells 1–10 µg/mL 2–4 hours Evaluate macrophage phagocytosis of ES cells, MAG significantly increased macrophage phagocytosis of ES cells J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
EWS502 cells 1–10 µg/mL 2–4 hours Evaluate macrophage phagocytosis of ES cells, MAG significantly increased macrophage phagocytosis of ES cells J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
A673 cells 1–10 µg/mL 2–4 hours Evaluate macrophage phagocytosis of ES cells, MAG significantly increased macrophage phagocytosis of ES cells J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
BT474 10 μg/mL 2 hours To evaluate the phagocytic effect of Magrolimab combined with trastuzumab on HER2-positive breast cancer cells. Results showed that the combination treatment significantly increased macrophage-mediated phagocytosis. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118
SKBR3 10 μg/mL 2 hours To evaluate the phagocytic effect of Magrolimab combined with trastuzumab on HER2-positive breast cancer cells. Results showed that the combination treatment significantly increased macrophage-mediated phagocytosis. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118
ES cells (A673, TC32, SKNMC) 1 µg/mL 2-4 hours To evaluate the effect of MAG on macrophage phagocytosis of ES cells, results showed MAG significantly enhanced macrophage phagocytic activity against ES cells. J Immunother Cancer. 2024 Sep 12;12(9):e009726
Lymphoma cell lines (Granta 519, Carnaval, DG-75, MEC2, SU-DHL-4) 10 µg/ml 2 hours To evaluate the effect of Magrolimab (CD47-IgG s) in combination with rituximab on macrophage-mediated ADCP. Results showed that Magrolimab significantly enhanced the ADCP effect of rituximab on various lymphoma cell lines. Front Immunol. 2022 Oct 27;13:929339

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice ES xenograft model Intraperitoneal 150 µg/animal Once per day for 12 days Evaluate the effect of MAG on ES tumor growth and animal survival, MAG significantly reduced tumor burden and prolonged survival J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
NSG mice HER2-positive breast cancer xenograft model Intraperitoneal injection 250 μg every other day Trastuzumab once a week, Magrolimab every other day for 7 weeks To evaluate the antitumor effect of Magrolimab combined with trastuzumab on HER2-positive breast cancer xenograft models. Results showed that the combination treatment significantly inhibited tumor growth and maintained efficacy after treatment cessation. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118
NSG mice ES cell (A673-luc) or ES patient-derived xenograft (PDX) tumor model Intraperitoneal 100 µg/animal Once per day for 12 days To evaluate the effect of MAG on ES tumor growth and metastasis in vivo, results showed MAG alone or in combination with CAR-NK and NKTR-255 significantly decreased primary tumor growth and lung metastasis, and extended animal survival. J Immunother Cancer. 2024 Sep 12;12(9):e009726
NSG-SGM3 mice Humanized mouse model Intraperitoneal injection 6 mg/animal, 12-100 mg/animal From day 4 to day 22 with dose escalation Evaluation of CD47 blockade efficacy in the humanized Ewing sarcoma mouse model showed that magrolimab significantly reduced primary tumor growth, decreased lung metastasis, and prolonged animal survival. Front Immunol. 2023 Oct 6;14:1277987

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02216409 Solid Tumor PHASE1 COMPLETED 2025-12-18 Stanford Cancer Institute, Sta... More >>nford, California, 94305, United States|University of Chicago, Chicago, Illinois, 60637, United States|START Midwest, Grand Rapids, Michigan, 49503, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|University of Oklahoma, Oklahoma City, Oklahoma, 73104, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States Less <<
NCT05169944 Brain Cancer|Malignant Brain T... More >>umor|Recurrent Brain Tumor|Progressive Malignant Brain Tumor|Brain Tumor, Pediatric|Brain Tumor Adult Less << PHASE1 COMPLETED 2024-09-30 University of California, San ... More >>Francisco, San Francisco, California, 94143, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|University of Utah, Salt Lake City, Utah, 84113, United States Less <<
NCT05627466 Relapsed/Refractory Acute Myel... More >>oid Leukemia Less << NO_LONGER_AVAILABLE - -
NCT02678338 Acute Myeloid Leukemia|Myelody... More >>splastic Syndrome Less << PHASE1 COMPLETED 2025-02-19 University Hospital of Wales, ... More >>Cardiff, United Kingdom|St. James University Hospital, Leeds, United Kingdom|The Royal Liverpool University Hospital, Liverpool, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom Less <<
 

Historical Records

Categories